Maximus Review
Semaglutide & tirzepatide GLP-1 weight-loss telehealth · Independently scored 7.2/10
Best for: brand-name GLP-1 pills and pens sold next to compounded tirzepatide and men's health care
Maximus falls below our bar on oversight: the FDA has issued it a warning letter. Its compounded tirzepatide costs $99.99 a month, paid up front, 63% below the $269 median among the sellers we compare.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
charged as a multi-month plan up front
Covered by the monthly price
Medication
In the price
Clinician visits
Not stated
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
Prices checked October 2026
Maximus is a men's health platform that also sells GLP-1 weight-loss care to men and women in 47 states. Compounded tirzepatide is one flat rate at every dose, billed up front: $199.99 a month on a 2-month plan down to $99.99 on a 12-month plan. Six brand-name drugs start at $199.99 a month for Foundayo. Its compounded GLP-1 marketing drew an FDA warning letter dated June 8, 2026.
Is Maximus legit?
Maximus is a real, operating US company, and the FDA has issued it a warning letter. The letter is summarized at the top of this review. Read what it alleges before you decide, and raise it with the clinician who would prescribe for you. We rate Maximus 7.2/10 overall.
Is there a Maximus promo or coupon code?
We know of no promo or coupon code for Maximus. Its listed price is $99.99 a month. Coupon sites advertising "Maximus discount codes" are not a source we can vouch for, and any genuine offer shows at checkout without a code.
See how Maximus compares on our rankings of the best semaglutide providers and the best tirzepatide providers.
Vetted alternatives to Maximus
Collective
Best for: flat any-dose pricing, if you can absorb a $199 annual membership on top
Editorial score · methodology
Embody
Best for: a flat compounded tirzepatide or semaglutide price at every dose, from a seller that names its pharmacies
Editorial score · methodology
Luvo Health
Best for: moving between compounded and brand without changing seller
Editorial score · methodology
Maximus at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Tirzepatide
- Starting price
- $99.99/mo
- Pricing model
- Flat: the price stays the same as the dose goes up
- What's included
- Medication · Shipping
- Availability
- 47 states
- FDA status
- 1 FDA warning letter (details below)
How Maximus scores
Six columns, each one computed from something Maximus has published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where a seller keeps something back, such as its price or its pharmacy, the score reflects it. Every seller we review goes through the same six columns.
Value25%
6.0/10$99.99/month is 63% below the $269 median for compounded tirzepatide across the sellers we compare. Every listed price requires paying for several months up front, so Value is capped at 6.
Effectiveness25%
10.0/10Dispenses orforglipron, semaglutide and tirzepatide, including the FDA-approved product. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).
User Experience15%
7.5/10A price is shown before the questionnaire starts. A live video visit is required, which is slower but the more careful intake.
Trust & Safety15%
4.5/10The FDA has issued it a warning letter. No pharmacy is named for its prescriptions. It shows a price before asking for health information. It lists the states it serves.
Accessibility10%
9.5/10Serves 47 of 50 states.
Support10%
4.5/10The price covers the medication and shipping.
A seller that shows no price until after the medical intake loses points on User Experience and Trust & Safety, and its review says so. How we score →
What we checked on Maximus
Last checked October 2026- Checked the listed price across 11 dose or plan tiers
- Checked state coverage: 47 states
- Checked what the monthly price covers, and what it leaves out
- Checked FDA warning letters for Maximus
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below.
What signing up with Maximus involves
What to expect on the way to a prescription: where the price appears, who fills the medication, and what the monthly price covers. It is not medical advice, and a clinician makes the prescribing decision.
- 1Maximus shows a price on its own site before asking anything about you, so you can compare it with other sellers before you start a questionnaire.
- 2The intake requires a live video visit with a clinician before a first prescription, which takes longer than a written form and is the more careful route.
- 3Ask Maximus which pharmacy fills the prescription before you pay. The pharmacy's name is what lets you check its license.
- 4The monthly price includes the medication and shipping.
- Lowest ongoing monthly price: tirzepatide $99.99. That leaves out membership fees, first-month rates and insurance copays.
- Maximus serves 47 of 50 states, so check that yours is one of them.
- The FDA has issued Maximus a warning letter. It is covered in the enforcement section below; read what it alleges before you decide.
- The medication is compounded, so it is not an FDA-approved product and has not been reviewed by the agency for safety, effectiveness or manufacturing quality.
Cancelling Maximus
Taken from the terms Maximus publishes. Terms change, so check the current policy before you subscribe.
- Cancel any time
- Yes
- Minimum commitment
- Compounded plans run 2, 4, 6 or 12 months, billed up front
- Refund policy
- Full refund minus the consultation if not approved; none once medicine ships
Medications Maximus lists
Maximus lists Wegovy, Ozempic, Zepbound, Mounjaro, Foundayo and compounded tirzepatide. Each one has its own guide: how it works, the dosing schedule, the side effects that show up in practice, and what the trials measured.
Peptides Maximus offers
Maximus sells peptides beyond the GLP-1s. Tap one to read what the evidence says about it.
Pricing
Prices re-verified
Shortest plan offered; there is no month-to-month option. Ships every 2 months.
Same flat rate at every dose.
Same flat rate at every dose.
Renews at the same rate at the end of the term unless canceled.
Low-dose protocol for metabolic health; plan length not stated.
Starting price on the weight-loss page; the plan length behind it is not stated.
Starting price on the weight-loss page; the plan length behind it is not stated.
Starting price on the weight-loss page; the plan length behind it is not stated.
Starting price on the weight-loss page; the plan length behind it is not stated.
Pen or vial at the same self-pay price. Starting price on the weight-loss page; the plan length behind it is not stated.
Starting price on the weight-loss page; the plan length behind it is not stated.
Check the price yourself before you pay
Every figure here comes from Maximus's own website, as of the date shown. Sellers move prices without announcing it, and promotional rates lapse, so confirm the standing cost on their site before committing.
In its favor
- Tirzepatide costs $99.99 a month, 63% below the $269 median for compounded tirzepatide across the sellers we compare
- Shows its price before the medical questionnaire, so you can compare it without handing over health information
- The monthly price stays the same as your dose goes up
- The monthly price includes the medication and shipping
- Serves 47 states
- A live video visit with a clinician is required before a prescription, which is slower than a form and is the more careful intake
Against it
- Ask which pharmacy fills the prescription before you pay, so you can check its license
- The FDA has issued Maximus a warning letter. Read what it alleges: a letter flags a problem but does not by itself rule a seller out
- Its compounded tirzepatide is not FDA-approved, so it has not been reviewed by the agency for safety, effectiveness or manufacturing quality
What Maximus charges
The standing price at Maximus is $99.99/month, unchanged as the dose goes up. That sits at the affordable end of what we see. Flat dose pricing matters more than it sounds: on a tiered plan the bill grows with the dose, so the figure that got you to sign up is not the one you end up paying.
- Compounded tirzepatide (2-month plan): $199.99/month
- Compounded tirzepatide (4-month plan): $149.99/month
- Compounded tirzepatide (6-month plan): $119.99/month
- Compounded tirzepatide (12-month plan): $99.99/month
- Compounded tirzepatide (microdose): $132.99/month
- Foundayo tablet: $199.99/month
For compounded tirzepatide, the median across the sellers we compare is $269/month, so Maximus' $99.99 is genuinely below the middle, not just advertised that way. Some of Maximus' plans are paid several months up front, so read the terms you agree to at checkout before you choose a longer one.
Oak, at about $100/month, is the closest like-for-like alternative we review.
What Maximus dispenses
Maximus prescribes semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the pair carrying the strongest published outcome data. Both routes are available: the FDA-approved pen, or a compounded version at lower cost. The difference is not cosmetic. The approved product has been reviewed for safety, efficacy and manufacturing quality, and a compounded preparation has not. The molecule can be the one in Ozempic and Wegovy; what differs is the formulation, the concentration and the dose ladder. Maximus also lists a microdose plan, and the published evidence on GLP-1 microdosing is letters and commentary rather than trials. Foundayo is the GLP-1 pill with no fasting rule, approved in April 2026.
Safety and disclosure
Maximus tells you its price before you start the medical questionnaire and the 47 states it serves. The FDA has issued Maximus a warning letter, summarized at the top of this page. A letter flags a problem rather than ruling a seller out, so read what it says before deciding what it means for you. Because the medication is compounded, the most useful question to ask at intake is which licensed pharmacy fills the prescription. If Maximus will not tell you, treat that as a warning sign. Across the market, the FDA's GLP-1 warning letters are mostly about what sellers said rather than what pharmacies made. How we weigh oversight, disclosure and price is set out in our scoring methodology.
Who should look elsewhere
- You need insurance to cover the cost. Check whether Maximus bills your plan before you start.
- A seller's regulatory history matters to you more than price. Read the warning letter summarized above before deciding.
It fits if
- the lowest standing monthly cost is what you are solving for
- you want the price to stop moving as your dose climbs
Our read
Maximus competes on price, and at $99.99/month it competes well. The FDA warning letter is what to weigh against that, not a footnote to it. Whatever you decide, read the warning letter summarized at the top of this page first, and raise it with the clinician who would prescribe for you.
The Bottom Line
Maximus falls below our bar on oversight: the FDA has issued it a warning letter. Its compounded tirzepatide costs $99.99 a month, paid up front, 63% below the $269 median among the sellers we compare.
Before you pay Maximus
Starting at $99.99 a month. Check today's price, then start the intake.
Where Maximus is the wrong choice
No seller suits every reader, and pretending otherwise is the easiest way to sell one. On these two counts, another seller does better.
- If the standing monthly cost is what decides it, consider WellMedRx (from $49/mo).
- If you want a human checking in, not just a prescription, consider Eden.
If none of these fits, our guide to alternatives to Maximus sets more sellers in the same category beside Maximus on price, states and what the price includes.
Frequently Asked Questions
How to check Maximus yourself
- Buying Tirzepatide as a Research Chemical: What "Research Use Only" Really Means
- How to Read a Peptide Certificate of Analysis (and What It Cannot Prove)
- FDA Warning Letters to Peptide Sellers: What FDA Has Cited, 2023 to 2026
Every seller that ships to your state, side by side: California, Maryland, Montana, Ohio, Oregon, Tennessee, Vermont, Virginia and every other state.
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Regulatory notice
Maximus has an FDA warning letter on record, dated June 8, 2026
This letter concerns false & misleading claims/misbranded (telehealth). A warning letter is public correspondence from FDA, not an adjudication. On its own it establishes no finding of illegal activity, and a company that gets one often answers with corrective action.
Sources
Cited across this Maximus review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of October 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Aronne LJ et al.)— New England Journal of Medicine.PMID: 40353578.
See Maximus's current pricing
Plans start at $99.99 a month. Whether you qualify is a clinician's decision, made after your intake.